Table 2.
Univariate and multivariate analyses of OS and PFS
| Variable | OS |
PFS |
||||||
|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariate |
Univariate |
Multivariate |
|||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Diagnosis (ethmoid vs. others) | 3.52 (1.68–7.39) | <0.01 | 2.87 (0.54–15.32) | 0.22 | 2.01 (1.00–4.06) | 0.05 | 1.57 (0.39–6.42) | 0.53 |
| Histologic type (ACCa vs. others) | 0.68 (0.32–1.47) | 0.33 | 0.88 (0.50–1.53) | 0.64 | ||||
| T stage (T4 vs. T2-3) | 1.38 (0.78–2.45) | 0.27 | 0.82 (0.51–1.31) | 0.4 | ||||
| Op (yes vs. no) | 0.72 (0.38–1.34) | 0.31 | 0.72 (0.44–1.18) | 0.19 | ||||
| RM (close or positive vs. negative) | 2.17 (0.81–5.81) | 0.12 | 2.05 (0.74–5.68) | 0.17 | 2.75 (1.21–6.25) | 0.02 | 2.65 (1.15–6.08) | 0.02 |
| PNI (yes vs. no) | 0.65 (0.15–2.72) | 0.55 | 0.55 (0.18–1.71) | 0.3 | ||||
| LVI (yes vs. no) | 1.91 (0.37–9.85) | 0.44 | 1.30 (0.36–4.72) | 0.69 | ||||
| CTx (yes vs. no) | 1.74 (0.94–3.20) | 0.08 | 1.50 (0.40–5.56) | 0.55 | 1.57 (0.98–2.54) | 0.06 | 1.33 (0.53–3.33) | 0.54 |
| RT (yes vs. no) | 1.13 (0.45–3.26) | 0.8 | 1.25 (0.54–2.87) | 0.61 | ||||
| ENT (yes vs. no) | 1.15 (0.60–2.21) | 0.67 | 1.06 (0.39–2.86) | 0.91 | 1.19 (0.72–1.95) | 0.5 | 1.39 (0.69–2.83) | 0.36 |
| Neoadjuvant RT and/or CTx (yes vs. no) | 0.45 (0.06–3.27) | 0.43 | 0.68 (0.21–2.16) | 0.51 | ||||
| Adjuvant RT and/or CTx (yes vs. no) | 0.72 (0.40–1.30) | 0.27 | 0.84 (0.52–1.35) | 0.46 | ||||
OS, overall survival; PFS, progression free survival; HR, hazard ratio; CI, confidence interval; ACCa, adenoid cystic carcinoma; Op, operation; RM, resection margin; PNI, perineural invasion; LVI, lymphovascular invasion; CTx, chemotherapy; RT, radiotherapy; ENT, elective neck treatment.